Physician profile
Amit Joglekar
NPI 1891879045
$2,111.41
in general payments reported to CMS, 2019-2025
10 companies · $41.18 in 2025
The $41.18 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $62.97 · 2021: $70.54 · 2022: $275 · 2023: $1,403 · 2024: $15.27 · 2025: $41.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,023 · Food and Beverage: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,022.93 |
| Food and Beverage | $436.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,411.53 | 2023-2025 | Illumisite |
| Glaxosmithkline, LLC. | $297.50 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Actelion Pharmaceuticals US, INC. | $96.78 | 2019-2022 | |
| Harmony Biosciences LLC | $80.21 | 2021-2022 | |
| Mylan Specialty L.P. | $80.03 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $63.78 | 2019-2021 | |
| Genzyme Corporation | $23.81 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.70 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.35 | 2020 | |
| Shire North American Group INC | $16.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Joglekar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.